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Purpose: The present study was undertaken to develop a validated, rapid, simple and low-cost 
ultraviolet (UV) spectrophotometric method for estimating levofloxacin (LFX) in dosage preparations. 
Method: UV spectrophotometric analysis was performed spectrophotometrically at a pre-determined 
λmax of 290 nm with 0.1M HCl as diluent/blank. The method was validated for linearity, accuracy, 
precision, reproducibility, and specificity as per International Conference on Harmonization (ICH) 
guidelines. The method was also used in the determination of the content of levofloxacin in two 
commercial brands of levofloxacin in the Nigerian market. 
Results: The regression data for the calibration plots exhibited good linear relationship (r = 0.999) over 
a concentration range of 0.25 – 12.0 µg/ml and the linear regression equation was y = 0.075x + 0.018. 
Mean recovery accuracy was 98.7 %, which was not significantly different from the expected value (p = 
0.05), while coefficient of variation (CV) for both intra-day and inter-day was < 7 %. The method was 
specific for levofloxacin in the presence of common excipients, and when it was applied to two marketed 
brands, levofloxacin content was 99.69 ± 2.38 and 102.65 ± 3.64 %, respectively, of labeled claim. 
Conclusion: The proposed method gave good validation results and the statistical analysis performed 
proved that the method is precise, accurate and reproducible, and hence can be employed for routine 
analysis of LFX in bulk and commercial formulations. 
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INTRODUCTION 
 
Quinolones comprise an interesting group of 
antibacterials whose action is based on their 
anti-DNA gyrase and topoisomerase IV 
activities. Their antibacterial activity is greatly 
increased by the addition of 6-fluoro and 7-
piperazinyl groups to the molecule giving rise 
to the novel 6-fluoroquinolones commonly 
referred to as the fluoroquinolone 
antibacterial agents. They are the second-
generation members of quinolones and are 
greatly effective against both Gram-negative 
and Gram-positive bacteria that are resistant 
to other antibacterials [1-3]. Levofloxacin, a 
newer member, is used in the treatment of 
MDR tuberculosis [4]. It is the L- isomer of 
ofloxacin existing commercially as the 
hemihydrate. Chemically, it is (-)-(S)-9-fluoro-
2,3-dihydro-3-methyl-10-(4-methyl-1-piperazi-
nyl)-7-oxo-7H--Pyrido[1,2,3-de]-1,4-benzoxa-
zine-6-carboxylic acid, hemihydrate.  
 
Bacterial resistance to antibiotics is an 
emerging public health crisis. The prevalence 
of pathogens resistant to currently available 
antibiotics is on the increase. The developing 
world, being an integral part of a ‘global 
village’, is not insulated from this trend. This 
has resulted in the influx of newer and more 
potent antibacterial agents, the fluoro-
quinolones inclusive, into these countries. 
Ascertaining the quality of the several brands 
of levofloxacin has become imperative. For 
most developing nations, acquisition of 
sophisticated chromatographic facilities for 
use in their laboratories is a capital intensive 
venture. This makes the development of a 
simple, rapid and cost-effective UV 
spectrophotometric method for the 
determination of active pharmaceutical 
ingredients (API) in formulated drug products 
a necessity.  
 
Several methods have been reported for the 
determination of quinolones in pure form, as 
well as in dosage forms and biological fluids. 
Nalidixic acid, norfloxacin, ciprofloxacin and 
its hydrochloride are official in both USP 
XXIV [5] and BP 1998 [6], while ofloxacin is 
official in USP XXIV only. Both USPXXIV and 
BP 1998 recommend high performance liquid 
chromatographic (HPLC) methods for the 
determination of ciprofloxacin in raw material 
and in dosage forms. USP XXIV 
recommends non-aqueous titration methods 
for the determination of nalidixic acid, 
norfloxacin and ofloxacin in raw material, 
while HPLC methods are described for the 
analysis of their dosage forms. BP 1998 
recommends a nonaqueous titration method 
for the determination of nalidixic acid. 
However, there is no pharmacopoeial UV 
spectrophotometric method for the 
determination of levofloxacin either in pure 
form or dosage form. The USP pending 
monograph 2009 proposed a complex liquid 
chromatographic (LC) method for the 
determination of its related substances and a 
titrimetric method for the assay of the raw 
material [7]. 
 
In this study, a simple UV spectrophotometric 
method was developed and validated as per 
International Conference on Harmonization 
(ICH) guidelines [8,9]. The method was also 
used in the determination of the content of 
levofloxacin in two marketed generic 






LFX was received as a gift from May and 
Baker Nigeria Plc, Lagos, Nigeria. 
Concentrated HCl (analytical grade) was 
purchased from Sigma Aldrich. Distilled water 
was used for all analysis. A Cecil 
spectrophotometer model number CE7200 
was used for the analysis. Excipients such as 
sodium starch glycolate (SSG), lactose, 
maize starch and microcrystalline cellulose 
(Avicel) were of pharmaceutical grade and 
obtained from May & Baker Nigeria Plc  
 
Determination of wavelength of maximum 
absorption 
 
Pure LFX (0.05 g) was dissolved in 50 ml of 
0.1M HCl and diluted to the 100 ml mark with 
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the same solvent. Ten millitres of this solution 
was further diluted to 100 ml with the same 
solvent to obtain a 50 µg/ml levofloxacin 
hemihydrate solution, Lo, which was scanned 
spectrophotometrically in the wavelength 
region 190 to 800 nm to determine the 




The 50 µg/ml levofloxacin solution, Lo, used 
for the wavelength of maximum absorption 
determination was employed as a stock 
solution for linearity study. Aliquots in the 
range of 0.05 to 3.5 ml of this solution were 
taken and diluted to 10 ml with the 0.1M HCl  
to obtain different concentrations within the 
range 0.25 – 12 µg/ml and used for the 
linearity calibration plot.  
 
Intra-day precision study 
 
Aliquots (0.5, 1.0 and 1.5 ml) of the 50 µg/ml 
levofloxacin stock solution were taken and 
respectively diluted to 100 ml with the 0.1M 
HCl to obtain three concentrations of 2.5, 5.0 
and 7.5 µg/ml, respectively. Triplicate 
absorbance measurements of each were 
made and the mean, standard deviation and 
RSD calculated. 
 
Inter-day precision study 
 
The selected concentrations for the intra-day 
precision study were again analysed the 
following day and the mean, standard 
deviation and RSD calculated 
 
Recovery accuracy study 
 
This study was carried out using pre-
formulated granules containing 70.2055 
%w/w pure levofloxacin hemihydrate, and 
common excipients including sodium starch 
glycolate (SSG), maize starch, lactose and 
avicel. The granulation (74 mg) was then 
transferred into a 100 ml volumetric flask.  
HCl (0.1M, 50 ml) was then added, shaken 
for 15 min using a vortex mixer and diluted to 
the 100 ml mark with the same solvent. The 
mixture was filtered to obtain sample stock 
solution, Po. This stock solution (1 ml) was 
further diluted to 100 ml with 0.1M HCl and 
then assayed for the content of levofloxacin 
using the proposed method with a solution 
containing 5 µg/ml of pure levofloxacin 
hemihydrates as standard for comparison. All 
analyses were carried out in triplicate. 
 
Specificity in the presence of excipients 
 
This test was carried out using common 
excipients including SSG, lactose, maize 
starch and avicel. Dummy granules devoid of 
the pure levofloxacin were prepared as in the 
recovery study above, their absorbance 
reading at 290 nm taken and compared with 
both that of the blank (0.1M HCl) and that 
obtained for the recovery study. 
 
Assay of content of levofloxacin in 
selected marketed brands 
 
This was carried out using the developed and 




Accurately weighed tablet powder, equivalent 
to 50 mg levofloxacin hemihydrate, was 
transferred into a 100 ml volumetric flask. An 
amount of 0.1M HCl (50 ml) was added, 
shaken for 15 min using a vortex mixer and 
diluted to the 100 ml mark with same solvent. 
It was then filtered to obtain sample stock 
solution, Po. One millilitre of the filtrate (Po) 
was further diluted to 100 ml with 0.1M HCl 
and then assayed for content of levofloxacin 
using the proposed method with a solution 
containing 5 µg/ml of pure levofloxacin 
hemihydrate as standard for comparison. All 
analyses were carried out in triplicate  
 
Reference standard preparation 
 
Pure LFX hemihydrate (50 mg) was 
accurately weighed and dissolved in 100 ml 
of 0.1M HCl. Out of this solution, 1 ml was 
further diluted to the 100 ml mark with the 
same solvent to obtain a 5 µg/ml levofloxacin 
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standard solution. The absorbances of the 
sample preparation and reference standard 
solution were taken using 0.1M HCl as blank. 
The content of anhydrous levofloxacin in the 
marketed brands was determined using Eqs 
1 and 2. 
 
LH (%)   =     (Ap x Ws)/(As x Wp)  x 100  ………  (1)  
 
where LH = content of levofloxacin 
hemihydrate (%w/w), Ap = absorbance  of  
generic sample solution, As = absorbance of 
reference levofloxacin  standard solution, Ws 
= weight of reference levofloxacin powder, 
and Wp = weight of generic powder sample. 
 
Hence, 
(L, %w/w) = 0.976 x LH  ….………………  (2) 
where L is the content of anhydrous 
levofloxacin; 
                  
D = (L x W20)/(20 x0.5)  ……..…………… (3) 
where D is % stated dose of anhydrous 
levofloxacin and W20  is the weight (g) of 20 
tablets of generic sample.  
     
Statistical analysis 
 
Where applicable, results were expressed as 
mean ± SD and analysed statistically using 
Student t-test with the aid of Excel 2007. 
Differences were considered significant at the 




The wavelength of maximum absorption 
(λmax) was 290 nm. The linearity parameter 
(Table 1) and the corresponding regression 
data, indicated excellent linear relationship (r
2
 
= 0.999) over the working concentration 
range (0.25 - 12.00 µg/ml). Table 2 presents 
the intra- and inter-day precision of the new 
method, confirming adequate sample stability 
and method reliability over a 24 h period. This 
is because for the three selected 
concentrations within the linearity range, the 
observed RSDs were all < 7 % and 
calculated values of t were less than the 
tabulated value of t at 95% confidence limit.  
 
Mean analyte recovery of 98.68 % with RSD 
of 0.99 %, was not statistically different from 
the expected recovery as the calculated 
value of t (1.9171) was substantially less than 
the tabulated value of 2.920 at the 95 % 
confidence level, thus indicating that the 
proposed method can satisfactorily be utilized 
to assay LFX in dosage forms. This was 
confirmed when the new method was used to 
determine the percent absolute drug content 
of LFX generics. The results indicated % 
label claims of 99.22 ± 2.38 to 102.65 ± 3.64 
%, respectively.  
 
Table 1: Linearity parameter data 
 
Parameter Result 
λmax (nm) 290 
Beer’s law linearity range (µg/mL) 0.25 to 12.0 
Regression equation  Y = 0.075X / 0.018 
Intercept (a)  0.018 
Slope (b)  0.075 
Correlation coefficient (r)  0.999 
N 17 
 
Although the method was not applied to liquid 
preparations such as injections, it seems 
likely that the observed recovery accuracy 
and precision for this type of dosage form 
would likely also be good since the liquid 
products may also not contain interferencing 
excipients at the λmax of 290 nm. However, 
further studies are onging to minimize 
 
   Table 2: Intra- and inter-day precision data (n = 3, p = 0.05) 
 
Mean absorbance ± SD 
 
Relative standard deviation 
(RSD, %) 
Conc. (µg/ml) 
Day 1 Day 2 Day 1 Day 2 
Calculated value of t 
2.5 0.208±0.001 0.209±0.003 0.4808 1.4350 0.7071* 
5.0 0.396±0.003 0.394±0.002 0.8183 0.5076 1.7889* 
7.5 0.566±0.005 0.561±0.004 0.8772 0.7130 3.3333* 
 
* No significant difference between day 1 and day 2 mean values at 95 % confidence level considering the tabulated t 
value of 4.3000 at 4 degree of freedom  
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interference that would likely result from the 
prsence of LFX’s related isomer, D-ofloxacin 




The developed method showed comparable 
accuracy and precision with LC methods. It 
was validated as per ICH guidelined [8-10] 
and the results of the validation parameters 
were within acceptable limits. The observed 
linearity range fitted well Beer-Lambert’s law 
and the corresponding regression coefficient 
(r = 0.999) is an indication of a high degree of 
method sensitivity. Recovery accuracy was 
good; so also was the precision of the 
method since RSD (< 7 %) which is within the 
allowable limit of ≤ 15% [10-12].  
 
When the developed method was applied to 
two commercial LFX brands, it demonstrated 
excellent reproducibility of the recovery 
accuracy and precision validation data; 
furthermore, the assay results were well 




The proposed UV spectrophotometric method 
is simple, rapid, selective, accurate, precise 
and highly sensitive. Therefore, it can be 
used for the determination of levofloxacin  
either in bulk or in their corresponding 
dosage forms without interference from 
commonly used excipients and related 
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